CLDN18.2 x CD3 TCE / CAR-T

About Integral Molecular

Integral Molecular is a privately held, revenue-generating biotechnology company that has established itself as an industry leader in membrane protein and antibody discovery technologies. The company operates a dual business model, providing fee-for-service research tools and reagent platforms while also developing its own preclinical therapeutic antibody pipeline for out-licensing. Its core strength lies in tackling difficult membrane protein targets, which are implicated in a wide range of diseases but have been historically challenging for drug discovery. Recent milestones include FDA qualification progress for its Membrane Proteome Array and the advancement of several bispecific and antibody-drug conjugate candidates into preclinical development.

Therapeutic Areas